First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

Small-cell lung cancer (SCLC) is an aggressive and rapidly growing disease with poor prognosis. Despite intense efforts to improve clinical outcomes, platinum/etoposide chemotherapy has remained the most effective regimen for first-line extensive disease SCLC for decades. The addition of immune chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Franco, A., Ackermann, C., Paz-Ares, L., Califano, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811117/
https://www.ncbi.nlm.nih.gov/pubmed/33450659
http://dx.doi.org/10.1016/j.esmoop.2020.100003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811117/
https://www.ncbi.nlm.nih.gov/pubmed/33450659
http://dx.doi.org/10.1016/j.esmoop.2020.100003

Ejemplares similares